Merck & Co., Inc., Bristol-Myers Squibb Company and Roche's Human Immune-Boosting Cancer Drugs Seen Extending Lives

Published: May 15, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Merck & Co. (MRK), Bristol-Myers Squibb Co. (BMY) and Roche Holding AG (ROG) have opened a new front against cancer with the next generation of experimental drugs that use the human immune system to seek and destroy tumor cells. The new therapies have the potential to reap billions of dollars in sales while lengthening patient remissions, said doctors and analysts awaiting study results to be released this week as part of the American Society of Clinical Oncology meeting that starts May 31. Building on the success of Bristol-Myers’ Yervoy drug for melanoma that reached the market in 2011, drugmakers are devising more potent immune therapies or combining treatments for maximum effectiveness. They are also testing the new medicines in more types of cancers, including lung and breast.

Help employers find you! Check out all the jobs and post your resume.

Back to news